Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study
Mepolizumab not only contributes to disease activity control but also reduces the GC dose, which may lead to improved survival in EGPA patients.
Authors
- Keiichiro Kadoba (ORCID: https://orcid.org/0000-0002-8242-9374)
- Mikihito Shoji
- Tsuneyasu Yoshida (ORCID: https://orcid.org/0000-0003-3114-8959)
- Motomu Hashimoto (ORCID: https://orcid.org/0000-0002-9241-060X)
- Akitoshi Takeda (ORCID: https://orcid.org/0000-0003-4911-9320)
- Ryosuke Hiwa (ORCID: https://orcid.org/0000-0001-6968-5712)
- Mayu Shiomi (ORCID: https://orcid.org/0009-0008-8992-1805)
- Yoshiaki Itoh (ORCID: https://orcid.org/0000-0001-5731-798X)
- Ayana Okazaki
- Takuya Kotani (ORCID: https://orcid.org/0000-0003-2190-0780)
- Wataru Yamamoto (ORCID: https://orcid.org/0000-0002-0810-4221)
- Ryosuke Tsuge
- Ryu Watanabe (ORCID: https://orcid.org/0000-0002-1089-5296)
- Shogo Matsuda (ORCID: https://orcid.org/0000-0002-8436-2046)
- Yuichi Masuda
Institutions
- Kyoto University (JP)
- Kurashiki Central Hospital (JP)
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.3389/fimmu.2024.1457202
- Citations
- 9
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.77